Instead of the CHIPS Act, the federal government could better incentivize technology innovations by ending the ability of ...
Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, and ...
"Teva stifled would-be generic competitors to QVAR because the drug laws do not allow for generic substitution of a given ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications. To date, the FTC’s Orange Book patent disputes have been ...
The FTC oversees consumer protections ... Faust: So with respect to these listings, which some people call "junk patents," it makes total sense when you're looking at something like some part ...
FTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA database Novo Holding’s proposed buyout of Catalent has sparked conversation across the industry about ...
It’s been a turbulent few days for GSK’s respiratory business: On Tuesday, the U.S. Federal Trade Commission (FTC) further cracked down on “junk patent listings,” including those related ...